Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,300 Mln
P/E Ratio
--
P/B Ratio
1.74
Industry P/E
--
Debt to Equity
0.01
ROE
-0.27 %
ROCE
-26.7 %
Div. Yield
0 %
Book Value
11.6
EPS
-2.45
CFO
$-847.38 Mln
EBITDA
$-890.09 Mln
Net Profit
$-1,062.90 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Celldex Therapeutics (CLDX)
| -22.56 | -5.82 | -18.53 | -47.14 | -16.18 | 45.41 | -26.94 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Celldex Therapeutics (CLDX)
| -36.05 | -11.02 | 15.35 | 120.55 | 685.65 | -24.88 | -92.93 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific... antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey. Read more
Founder, President, CEO & Director
Mr. Anthony S. Marucci M.B.A.
Founder, President, CEO & Director
Mr. Anthony S. Marucci M.B.A.
Headquarters
Hampton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Celldex Therapeutics Inc (CLDX) stood at $ 792 Mln as on 31-Dec-24
The share price of Celldex Therapeutics Inc (CLDX) is $19.57 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Celldex Therapeutics Inc (CLDX) has given a return of -16.18% in the last 3 years.
Celldex Therapeutics Inc (CLDX) has a market capitalisation of $ 1,300 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Celldex Therapeutics Inc (CLDX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Celldex Therapeutics Inc (CLDX) and enter the required number of quantities and click on buy to purchase the shares of Celldex Therapeutics Inc (CLDX).
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
The CEO & director of Mr. Anthony S. Marucci M.B.A.. is Celldex Therapeutics Inc (CLDX), and CFO & Sr. VP is Mr. Anthony S. Marucci M.B.A..
There is no promoter pledging in Celldex Therapeutics Inc (CLDX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Celldex Therapeutics Inc. (CLDX) | Ratios |
|---|---|
|
Return on equity(%)
|
-26.84
|
|
Operating margin(%)
|
-2778.89
|
|
Net Margin(%)
|
-2248.76
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Celldex Therapeutics Inc (CLDX) was $0 Mln.
$-0.01
(
